Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pandemic Perspectives: 20-Plus Vaccines In Development As India Tackles COVID-19 Surge

Will Exports Resume In August?

Executive Summary

From mRNA to subunit vaccines, Indian companies have 20 COVID-19 vaccine candidates, while three have already been approved. An August nod for Biological E could not just cut down time to immunize the country's population but also allow exports to resume.

You may also be interested in...



Watch Out Pfizer, Moderna - India’s First mRNA Vaccine Is Here

With India’s first and the world’s third mRNA vaccine, Gennova plans to provide access to its COVID-19 vaccine to those deprived of doses from Pfizer and Moderna. HDT Bio Corp’s suit in the US is not seen impacting marketing plans in India, COO tells Scrip

Is India’s Budget Bad News For COVID-19 Boosters, New Vaccines?

India’s 2022-23 budget cuts the outlay for COVID-19 vaccines to a seventh the previous amount. Is that worrying or does it leave the door open for private sales of vaccines? With over 75% of the country's adult population now fully vaccinated, what does it mean for booster shots and yet to be approved SARS-CoV-2 vaccines?

Eight COVID-19 Vaccines Approved In India In 2021, mRNA Addition Awaited

While an mRNA vaccine is still missing, 2021 saw Indian companies strike alliances, battle legal action and gain funding while the regulator played a crucial enabling role in the run up to the approval of eight COVID-19 vaccines from zero in 2020.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC144314

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel